Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia

Blood

Volumn 87, Issue 5, 1996, Pages 1997-2004

  Del Poeta, Giovanni ^a,b   Stasi, Roberto ^a   Aronica, Germano ^a   Venditti, Adriano ^a   Cox, Maria Cristina ^a   Bruno, Antonio ^a   Buccisano, Francesco ^a   Masi, Mario ^a   Tribalto, Maurizio ^a   Amadori, Sergio ^a   Papa, Giuseppe ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C 219; MONOCLONAL ANTIBODY JSB1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 13344282085     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.5.1997.bloodjournal8751997     Document Type: Article

References (48)

1. Ma DDF, Davey RA, Harman DH, Ibister JP, Scurr RD, Mackertich SM, Dowden G, Bell DR: Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. Lancet 1:135, 1987
2. Holmes J, Jacobs A, Carter G, Janowska-Wieczorek A, Padua RA: Multidrug resistance in hemopoietic cell lines, myelodisplastic syndromes and acute myeloblastic leukaemia. Br J Haematol 72:40, 1989
3. Carulli G, Petrini M, Marini A, Ambrogi F: P-glycoprotein in acute non-lymphoblastic leukemia and in the blastic crisis of myeloid leukemia. N Engl J Med 319:797, 1988
4. Marie JP, Zittoun R, Siki B: Multidrug resistance (MDR1) gene expression in adult acute leukemia: Correlation with treatment outcome and in vitro drug sensitivity. Blood 78:586, 1991
5. Michieli M, Damiani D, Geromin A, Michelutti A, Fanin R, Raspadori D, Russo D, Visani G, Dinota A, Pileri S, Tsunio T, Grandi M, Baccarani M, Tura S: Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukaemia. Eur J Haematol 48:87, 1992
6. Muller MR, Lennartz K, Boogen C, Nowrousian MR, Rajewsky MF, Seeber S: Cytotoxicity of adriamycin, idarubicin and vincristine in acute myeloid leukaemia: Chemosensitisation by verapamil in relation to P-glycoprotein expression. Ann Hematol 65:206, 1992
7. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H, Lechner K: MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83:708, 1991
8. Sato H, Preisler H, Day R, Raza A, Larson R, Browman G, Goldberg J, Vogler R, Grunwald H, Gottlieb A, Bennett J, Gottesman M, Pastan I: MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol 73:340, 1990
9. Zhou DC, Marie JP, Suberville AM, Zittoun R: Relevance of mdr1 gene expression in acute myeloid leukaemia and comparison of different diagnostic methods. Leukemia 6:879, 1992
10. Solary E, Bida JM, Calvo F, Chauffert B, Caillot D, Mugneret F, Gauville G, Tsuruo T, Carli PM, Guy H: P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma. Leukemia 5:595, 1991
11. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D: Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood 79:473, 1992
12. Pastan I, Gottesman M: Multiple-drug resistance in human cancer. N Engl J Med 316:1388, 1987
13. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc Natl Acad Sci USA 84:7735, 1987
14. Nooter K, Herweijer H. Multidrug resistance (mdr) geners in human cancer. Br J Cancer 63:663, 1991
15. Ito Y, Tanimoto M, Kumazawa T, Okumura M, Morishima Y, Ohno R, Saito H: Increased P-glycoprotein expression and multidrug-resistance gene (mdr1) amplification are infrequently found in fresh acute leukemia cells. Sequential analysis of 15 cases at initial diagnosis and relapsed stage. Cancer 63:1534, 1989
16. Mizuno J, Hara T, Nagata M, Tawa A, Tsuruo T, Ueda K: Detection of multidrug resistance protein, P-glycoprotein in childhood leukaemia and lymphoma. Eur J Pediatr 150:416, 1991
17. Sugawara I, Kodo H, Ohkochi E, Hamadas H, Tsuruo T, Mori S: High-level expression of MRK 16 and MRK 20 murine monoclonal antibody-defined proteins (170,000-180,000 P-glycoprotein and 85,000 protein) in leukaemias and malignant lymphomas. Br J Cancer 60:538, 1989
18. Ino T, Miyazaki H, Isogai M, Nomura T, Tsuzuki M, Tsuruo T, Ezaki K, Hirano M: Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays and correlation with treatment outcome. Leukemia 8:1492, 1994
19. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:620, 1985
20. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton AG, Gralnick HR, Sultan C: Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). Br J Haematol 78:325, 1991
21. Stasi R, Tribalto M, Venditti A, Del Poeta G, Aronica G, Zaccari G, Rossi V, Maffei L, Papa G: Simultaneous occurrence of monoclonal gammopathy and acute secondary leukemia with overexpression of P-glycoprotein. Tumori 78:403, 1992
22. Del Poeta G, Stasi R, Venditti A, Suppo G, Aronica G, Bruno A, Masi M, Tabilio A, Papa G: Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 8:388, 1994
23. Kartner N, Everden-Poreille D, Bradley G, Ling V: Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature 316:820, 1985
24. Scheper RJ, Bulte JWM, Brakker JGP, Quack JJ, Van Der School E, Balm AJM, Meijer CJLM, Broxterman HJ, Kutper CM, Lankelma J, Pinedo HM: Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug resistance. Br J Cancer 42:389, 1988
25. Grandi M, Geroni C, Giuliani FC: Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin. Br J Cancer 54:515, 1986
26. Dalton WS, Grogan TM, Rybski JA, Richter L, Kailey J, Broxterman HJ, Pinedo HM, Salmon SE: Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug resistant human myeloma cells: Association with level of drug resistance and drug accumulation. Blood 73:747, 1989
27. Stasi R, Del Poeta G, Masi M, Tribalto M, Venditti A, Papa G, Nicoletti B, Vernole P, Tedeschi B, Delaroche I, Mingarelli R, Dallapiccola B: Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genet Cytogenet 67:28, 1993
28. Resegotti L. for the GIMEMA Group: Treatment of acute nonlymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience. Leukemia 6:72, 1992 (suppl 2)
29. Avvisati G, Petti MC, Spadea A, Lazzarino M, Alessandrino EP, Liso V, Specchia G, Carella AM, Falda M, Fioritoni G, Ladogana F, Mandelli F for the cooperative group GIMEMA: Idarubicin (IDA) treatment in acute promyelocytic leukemia (APL): the GIMEMA experience. Haematologica 76.10, 1991 (suppl 4)
30. Zittoun R, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermans M, Dardenne M, Vegna ML, Petti MC, Solbu G, and Suciu S, for the EORTC and the GIMEMA Leukemia Cooperative Groups: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217, 1995
31. Zittoun R, Liso V, Mandelli F, Rotoli B, de Witte T, Gattringer C, Resegotti L, Caronia F, Leoni P, Petti MC, Solbu G, Vegna ML, Suciu S for the EORTC Leukemia Cooperative Group and the GIMEMA Group: Intensive consolidation chemotherapy vs standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC- Gimema phase III trial (AML 8B). Leukemia 6:76, 1992 (suppl 2)
32. Muller MR, Lennartz K, Nowrousian MR, Dux R, Tsuruo T, Rajewsky MF, Seeber S: Improved flow-cytometric detection of low P-glycoprotein expression in leukaemic blasts by histogram subtraction analysis. Cytometry 15:64, 1994
33. Del Poeta G, Stasi R, Venditti A, Cox C, Aronica G, Masi M, Bruno A, Simone MD, Buccisano F, Papa G: CD7 expression in acute myeloid leukemia. Leuk Lymphoma 17:111, 1995
34. Schinkel AH, Roelofs MEM, Borst P: Characterization of human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 51:2628, 1991
35. Thiebault F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Immunocytochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and cross-reactivity of one antibody with a muscle protein. J Histochem Cytochem 37:159, 1989
36. Cenciarelli C, Currier SJ, Willingham MC, Thiebaut F, Germann UA, Rutheford AV, Gottesman MM, Barca S, Tombesi M, Morrone S, Santoni A, Mariani M, Ramoni C, Dupuis ML, Cianfriglia M: Characterization by somatic cell genetics of a monoclonal antibody to the MDR1 gene product (P-glycoprotein): Determination of P-glycoprotein expression in multi-drug resistant KB and CEM cell variants. Int J Cancer 47:533, 1991
37. Schinkel AH, Arceci RJ, Smit JJM, Wagenaar E, Baas F. Dolle' M, Tsuruo T, Mechetner EB, Roninson IB, Borst P: Binding properties of monoclonal antibodies recognizing external epitopes of the human, MDR1 P-glycoprotein. Int J Cancer 55:478, 1993
38. Arceci RJ: Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81:2215, 1993
39. Hart SM, Ganeshaguru K, Lyttelton MP, Prentice HG, Hoffbrand AV, Mehta AB: Flow cytometric assessment of multidrug resistance (MDR) phenotype in acute myeloid leukaemia. Leuk Lymphoma 11:239, 1993
40. te Boekhorst PAW, de Leeuw K, Schoester M, Wittebol S, Nooter K, Hagemeijer A, Lowenberg B, Sonneveld P: Predominance of functional multidrug resistance (mdr-1) phenotype in CD34+ acute myeloid leukemia cells. Blood 85:3157, 1993
41. Nuessler V, Pelka-Fleischer R, Nerl C, Beckert B, Wilmanns W: P-glycoprotein expression in patients with acute leukemia, chronic leukemia and myelodysplastic syndromes. J Cancer Res Clin Oncol 117:S114, 1991 (suppl 3)
42. Sato H, Gottesman MM, Goldstein LJ, Pastan I, Block AM, Sandberg AA, Preisler HD: Expression of the multidrug resistance gene in myeloid leukemias. Leuk Res 14:11, 1990
43. Musto P, Melillo L, Lombardi G, Matera R, Di Giorgio G. Carotenuto M: High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotem positive cells in complete remission. Br J Haematol 77:50, 1991
44. Paietta E, Andersen J, Racevskis J, Gallagher R, Bennett J, Yunis J, Cassileth P, Wiernik PH: Significantly lower P-glycoprotein expression in acute promyelocitic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses. Leukemia 8:968, 1994
45. Fojo A, Lebo R, Shimizu N, Chin Je, Roninson IB, Merlino GT, Gottesman MM, Pastan I: Localization of multidrug resistance associated DNA sequences to human chromosome 7. Somatic Cell Mol Genet 12:415, 1986
46. - acute myeloblastic/acute lymphoblastic leukemia. Blood 82:3445, 1993
47. Stasi R, Del Poeta G, Venditti A, Masi M, Stipa E, Dentamaro T, Cox C, Dallapiccola B, Papa G: Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood 83:1619, 1994
48. Venditti A, Del Poeta G, Stasi R, Masi M, Bruno A, Buccisano F, Cox C, Coppetelli U, Aronica G, Simone MD, Tribalto M, Amadori S, Papa G: Minimally differentiated acute myeloid leukemia (AML-M0): Cytochemical, immunophenotypic and cytogenetic analysis of 19 cases. Br J Haematol 88:784, 1994